Tin tức & Cập nhật

Chỉ hiển thị Multimedia

Biologic dose optimization not needed in UC patients with early nonresponse, high drug clearance

27 Nov 2023

For patients with ulcerative colitis who are receiving vedolizumab, dose optimization may not be required in the presence of early nonresponse to treatment as well as high drug clearance, according to data from the phase IV ENTERPRET study.

Biologic dose optimization not needed in UC patients with early nonresponse, high drug clearance

27 Nov 2023

Palliative care in cancer: Which central venous access devices are associated with higher complication rates?

27 Nov 2023 bởi

A systematic review and meta-analysis by researchers from the University of Hong Kong has shown that the use of peripherally inserted central catheters (PICCs) is associated with a higher rate of complications than central lines in terminally ill cancer patients with central venous access devices (CVADs) for palliative care. No conclusions were reached regarding the use of totally implanted ports (PORTs), as no studies on PORTs were eligible for analysis.

Palliative care in cancer: Which central venous access devices are associated with higher complication rates?

27 Nov 2023

Novel tri-agonist confers significant gains for MASLD patients

24 Nov 2023 bởi

In a substudy of a phase II obesity trial, individuals with MASLD* and obesity benefited significantly from retatrutide, a once-weekly, injectable, novel synthetic molecule that has shown potent agonist action at GIP**, GLP-1***, and glucagon receptors.

Novel tri-agonist confers significant gains for MASLD patients

24 Nov 2023

Cholecystectomy during pregnancy supported in large study

24 Nov 2023

For expectant mothers with acute cholecystitis (AC), undergoing cholecystectomy lowers the risk of adverse pregnancy outcomes, according to a large study.

Cholecystectomy during pregnancy supported in large study

24 Nov 2023

Bulevirtide-PegIFNα combo yields benefits for CHD patients

21 Nov 2023 bởi

A combination regimen comprising bulevirtide 10 mg (BLV10) and pegylated interferon alpha-2a (PegIFNα) improved multiple liver parameters in patients with chronic hepatitis delta (CHD), findings from the phase IIb MYR204 study have shown.

Bulevirtide-PegIFNα combo yields benefits for CHD patients

21 Nov 2023

Semaglutide reduces CV risk in overweight/obese patients without T2D

21 Nov 2023 bởi

Treatment with semaglutide reduced the risk of major adverse cardiovascular events (MACE) among overweight/obese patients with pre-existing cardiovascular (CV) disease but without type 2 diabetes (T2D), according to the SELECT trial presented at AHA 2023.

Semaglutide reduces CV risk in overweight/obese patients without T2D

21 Nov 2023

8-week TAF course enough to prevent mother–child HBV transmission

20 Nov 2023 bởi

An 8-week course is as good as a 12-week course of tenofovir alafenamide fumarate (TAF) therapy in terms of preventing the transmission of hepatitis B virus (HBV) infection from mothers to infants, as reported in a study.

8-week TAF course enough to prevent mother–child HBV transmission

20 Nov 2023

Chronic HBV infection may up risk of intracerebral haemorrhage

17 Nov 2023

Chronic hepatitis B virus (HBV) infection appears to put Chinese adults at higher risk of intracerebral haemorrhage but not other stroke subtypes, as reported in a study.

Chronic HBV infection may up risk of intracerebral haemorrhage

17 Nov 2023

Early life antibiotic, acid suppressant exposure linked to eosinophilic esophagitis in childhood

15 Nov 2023

Maternal and infant use of antibiotic and acid suppressants appears to contribute to an increased risk of eosinophilic esophagitis in a dose-response manner, with the association being strongest when exposed to the medications near the time of delivery, according to a study.

Early life antibiotic, acid suppressant exposure linked to eosinophilic esophagitis in childhood

15 Nov 2023

Osemitamab plus CAPOX proven safe, prolongs survival in advanced G/GEJ cancer

15 Nov 2023 bởi

First-line treatment with TST001 (osemitamab) in combination with capecitabine and oxaliplatin (CAPOX) is safe and well tolerated in patients with advanced gastric/gastroesophageal junction (G/GEJ) cancer, according to a study presented at ESMO 2023.

Osemitamab plus CAPOX proven safe, prolongs survival in advanced G/GEJ cancer

15 Nov 2023

Tin tức & Cập nhật

Lọc theo Chuyên ngành:

Chuyên ngành:

Biologic dose optimization not needed in UC patients with early nonresponse, high drug clearance

Biologic dose optimization not needed in UC patients with early nonresponse, high drug clearance

Palliative care in cancer: Which central venous access devices are associated with higher complication rates?

Palliative care in cancer: Which central venous access devices are associated with higher complication rates?

Novel tri-agonist confers significant gains for MASLD patients

Novel tri-agonist confers significant gains for MASLD patients

Cholecystectomy during pregnancy supported in large study

Cholecystectomy during pregnancy supported in large study

Bulevirtide-PegIFNα combo yields benefits for CHD patients

Bulevirtide-PegIFNα combo yields benefits for CHD patients

Semaglutide reduces CV risk in overweight/obese patients without T2D

Semaglutide reduces CV risk in overweight/obese patients without T2D

8-week TAF course enough to prevent mother–child HBV transmission

8-week TAF course enough to prevent mother–child HBV transmission

Chronic HBV infection may up risk of intracerebral haemorrhage

Chronic HBV infection may up risk of intracerebral haemorrhage

Early life antibiotic, acid suppressant exposure linked to eosinophilic esophagitis in childhood

Early life antibiotic, acid suppressant exposure linked to eosinophilic esophagitis in childhood

Osemitamab plus CAPOX proven safe, prolongs survival in advanced G/GEJ cancer

Osemitamab plus CAPOX proven safe, prolongs survival in advanced G/GEJ cancer